Appendix 4E and 2026 Annual Report

• FY2026 loss down 4.4% to $(7,002,637)
• Net assets increased to $14,200,812
• PTX-100 Phase 2a trial expanded to 12 sites
• Secured Orphan Drug Designations in US and EU
• Appointed Dr Rosalind Wilson as Chief Medical Officer

Prescient Therapeutics Limited reported a 4.4% decrease in loss for the year ended 30 June 2026, down to $(7,002,637) from $(7,322,531) in the previous year. The company's net assets increased to $14,200,812, up from $11,387,172 in the prior year. The PTX-100 Phase 2a clinical trial, targeting cutaneous T-cell lymphoma (CTCL), expanded to 12 active sites across the United States, Australia, and Italy. The company secured Orphan Drug Designations from both the U.S. FDA and the European Medicines Agency (EMA), providing market exclusivity and reduced fees in these markets. Dr Rosalind Wilson was appointed as Chief Medical Officer in July 2026.

Prescient Therapeutics plans to complete European site activation, progress enrolment, and manage the business efficiently for FY2027.